Prosecution Insights
Last updated: October 04, 2026
Application No. 18/841,784

BIODEGRADABLE ARTIFICIAL BAIT COMPOSITION AND BIODEGRADABLE ARTIFICIAL BAIT

Non-Final OA §103
Filed
Aug 27, 2024
Priority
Mar 31, 2022 — JP 2022-059537 +1 more
Examiner
ALLEY, GENEVIEVE S
Art Unit
Tech Center
Assignee
Dainichiseika Color & Chemicals Mfg. Co., Ltd.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
444 granted / 736 resolved
At TC average
Strong +48% interview lift
Without
With
+48.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
35 currently pending
Career history
777
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
49.7%
+9.7% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
18.8%
-21.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 736 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-4 and 6 are rejected under 35 U.S.C. 103 as being unpatentable over Jari et al. (CN 113453545; published: 9/28/21). The English language machine translation of CN 113453545 is attached herein. The passages cited below which indicate the teachings of the ‘545 publication are based on its English translation. Determination of the Scope and Content of the Prior Art (MPEP §2141.01) Jari is directed to a mouldable composition for manufacturing a fishing bait [Title]. With regards to instant claims 1-2, Jari teaches a moldable composition for the manufacture of fishing bait, comprising: a base solution comprising water, a gelling agent, a plasticizer and at least one crosslinking agent [claim 1]. Jari teaches wherein the gelling agent is gelatin [claim 4], wherein the plasticizer is a sugar alcohol, such as glycerol, sorbitol, mannitol, xylitol or erythrose alcohol [claim 7], wherein the base solution comprises 5-50 wt% gelatin, preferably 10-50 wt% gelatin, more preferably 20-50 wt% gelatin [claim 9], wherein the base solution comprises 15-60 wt% sugar alcohol, preferably 20-60 wt% sugar alcohol, more preferably 30 - 60 wt% sugar alcohol [claim 10], wherein the base solution comprises 5-50 wt % water, preferably 20-50 wt % water, more preferably 20-40 wt % % water [claim 11], wherein the cross-linking agent comprises a polyphenol of plant origin [claim 13], and wherein the moldable composition comprises 1-2 wt% of a crosslinking agent [claim 14]. With regards to instant claim 6, Jari teaches that the bait is directly moulded into a tray forming part of the consumer package and may resemble small fish, worms or other aquatic animals consumed by certain fish [p. 3]. Ascertainment of the Difference Between the Scope of the Prior Art and Claims (MPEP §2141.012) Although Jari teaches wherein the base solution comprises 5-50 wt% gelatin, preferably 10-50 wt% gelatin, more preferably 20-50 wt% gelatin [claim 9], Jari does not specifically teach the claimed range of 10-30% by mass of gelatin, as required by instant claim 1. Jari does not teach a particular embodiment wherein the abovementioned composition further comprises 0.01-10% by mass of a polysaccharide, as required by instant claim 3. However, it is noted that Jari teaches that the gelling agent may be a protein-containing gelling agent or a polysaccharide-containing gelling agent (e.g., pectin and agar) [p. 2]. The preferred gelling agent is gelatin, but other gelling agents may be used alone or in combination with gelatin [p. 2]. Although Jari is silent with regards to the bait composition having no cytotoxicity (via a cytotoxicity test specified in ISO 10993-5:2009), as required by instant claim 4. Finding of Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) As indicated in MPEP §2144.05(I): “In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists.” Based on these teachings of Jari, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to modify the embodiment described above containing a gelatin gelling agent by further incorporating a second gelling agent such as pectin or agar to achieve the predictable result of obtaining a composition suitable for providing a fishing bait. One of ordinary skill in the art would have been motivated to do so because Jari teaches that other gelling agents such as the polysaccharide-containing components (e.g., agar or pectin) may be used in combination with gelatin [p. 2]. The amount of each gelling agent (e.g., agar or pectin) is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ and would reasonably expect success. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each gelling agent in order to best achieve the desired results as such would provide advantageous product form (i.e., in the form of a gel). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to engage in routine experimentation to determine optimal or workable ranges that produce expected results. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. In re Aller, 220 F. 2d 454, 105 USPQ 233 (CCPA 1955). In the instant case, one of ordinary skill in the art understands that when an effective amount of a gelling agent is an aqueous suspension, a gel is formed, as such is the basic property of a gelling agent. The Examiner considers it prima facie obvious to optimize the amounts of any biologically active agent to achieve their known biological effect, absent unexpectedly superior properties of the claimed invention. In the instant case, one of ordinary skill in the art would have recognized that the amounts of each gelling agent would impact the formation of gelled fishing bait and therefore be an optimizable variable. However, the invention as claimed is not structurally distinguishable from the disclosure of Jari and it is therefore, the Examiner's position that cytotoxicity is an inherent property of the invention taught by Jari. Since the Patent and Trademark Office does not have the facilities for examining and comparing the claimed composition with the composition of Jari, the burden of proof is upon the Applicants to show an unobvious distinction between the structural and functional characteristics of the claimed composition and that of the prior art. See In re Best, 562 F.2d 1252, 195 U.S.P.Q. 430 (CCPA 197) and Ex parte Gray, USPQ 2d 1922 (PTO Bd. Pat. App. & Int.). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Thus, the claimed invention was prima facie obvious before the effective filing date of the claimed invention. Claim 5 is rejected under 35 U.S.C. 103 as being unpatentable over Jari et al. (CN 113453545; published: 9/28/21) as applied to claims 1-4 and 6 above, and further in view of Savage (WO 2021/217208; published: 11/4/21). The English language machine translation of CN 113453545 is attached herein. The passages cited below which indicate the teachings of the ‘545 publication are based on its English translation. Determination of the Scope and Content of the Prior Art (MPEP §2141.01) Jari teaches the limitations of instant claims 1-4 and 6 (see above rejection). Ascertainment of the Difference Between the Scope of the Prior Art and Claims (MPEP §2141.012) Although Jari teaches a fishing lure or fish bait that is moldable; i.e., can be molded by pouring into a mold and is allowed to stand until the moldable composition cures [p. 3], Jari does not specifically teach wherein the bait is formed into a block-like shape, a grain-like shape or a pellet-like shape, as required by instant claim 5. However, such deficiency is cured by Savage. Savage is directed to marine fishery trap baits and deterrents [Title]. Savage teaches that bait blocks can be places in bait baskets or lobster pots. Savage teaches that the moulds create the final block shape and dimensions are desired which benefits, for example, storage, placement and to fit within a bait holder of a trap [0080]. Finding of Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) Jari and Savage are both directed to fish bait products. Based on these teachings, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to modify the shape of Jari’s fish bait with the block shape taught by Savage to achieve the predictable result of obtaining a composition suitable for baiting fish. One of ordinary skill in the art would have been motivated to do so because Savage teach that it is advantageous for storage, placement and to fit within a baith holder of a trap [0080]. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Thus, the claimed invention was prima facie obvious before the effective filing date of the claimed invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to GENEVIEVE S ALLEY whose telephone number is (571)270-1111. The examiner can normally be reached Monday-Friday 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached at 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GENEVIEVE S ALLEY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Aug 27, 2024
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734149
Taxane Analogs for the Treatment of Brain Cancer
3y 0m to grant Granted Sep 15, 2026
Patent 12728177
Disinfectant Composition with Rapid Antiviral Efficacy
3y 4m to grant Granted Sep 08, 2026
Patent 12728166
Vaginal Hydrogel
2y 7m to grant Granted Sep 08, 2026
Patent 12721805
AMINOSILOXANE ESTER COPOLYMER AND METHODS FOR THE PREPARATION AND USE OF THE COPOLYMER
2y 11m to grant Granted Sep 01, 2026
Patent 12685720
COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS
1y 11m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+48.2%)
2y 11m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 736 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month